
KZR Stock Forecast & Price Target
KZR Analyst Ratings
Bulls say
Kezar Life Sciences Inc. has seen a positive shift in investor confidence following the lifting of the partial clinical hold in the autoimmune hepatitis (AIH) indication for its lead candidate, Zetomipzomib (KZR-616). The potential full removal of the clinical hold in lupus nephritis (LN) is expected to significantly boost investor sentiment and could facilitate clinical uptake if the product is approved. Overall, these developments may enhance the commercial prospects for Zetomipzomib, thereby positively influencing the company's future financial outlook.
Bears say
Kezar Life Sciences Inc. has demonstrated challenges in advancing its clinical-stage pipeline, particularly due to delays in clinical trials and the lengthy regulatory approval process typical of biotechnology firms. Additionally, the company faces significant cash burn rates which raise concerns about its ability to fund operations and development without securing further capital. Lastly, the competitive landscape in the biotechnology sector, coupled with the ongoing uncertainty surrounding the success of their product candidates like Zetomipzomib and KZR-261, contributes to a heightened risk for investors.
This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KZR Analyst Forecast & Price Prediction
Start investing in KZR
Order type
Buy in
Order amount
Est. shares
0 shares